Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 2026

Contributed by: Business Wire

Logo

Tags

Research

Surgery

Neurology

Clinical Trials

Other Health

General Health

Pharmaceutical

Health

Science

Other Science

PaiNT

More Like This

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 2026

Merz Therapeutics’ Activities at ISPRM 2026 Highlight the Importance of Patient-Centric Management in Upper and Lower Limb Spasticity: From Goal Setting to Optimal Dosing for Better Patient Outcomes

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

Business Wire embedded0

Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens